Mankind Pharma Share Price

Mankind Pharma may hike condom prices if the Middle East conflict persists and continues to keep oil prices elevated

• Business Line
• 4 days 17 hours ago

Pharmaceuticals company Mankind Pharma announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue for Q4FY26 stood at Rs 3,442.93 crore, a decline of 3.48% QoQ from Rs 3,567.20 crore in Q3FY26, and an increase of 11.81% YoY from Rs 3,079.37 crore in Q4FY25. Annual consolidated revenue for FY26 was Rs 14,277.64 crore, representing a growth of 16.96% YoY compared to Rs 12,207.44 crore in FY25. Total Income: Total income for Q4FY26 was Rs 3,557.22 crore, down 2.27% QoQ from Rs 3,639.95 crore, but up 6.80% YoY from Rs 3,330.70 crore. Annual total income for FY26 was Rs 14,636.43 crore, an increase of 14.85% YoY from Rs 12,744.23 crore in FY25. Profit Before Tax (from continuing operations): Consolidated PBT for Q4FY26 was Rs 659.17 crore, up 29.50% QoQ from Rs 509.00 crore and up 27.89% YoY from Rs 515.43 crore. For the full year FY26, PBT from continuing operations was Rs 2,332.68 crore, a decline of 7.30% YoY compared to Rs 2,516.33 crore in FY25. Net Profit for the Period/Year: Consolidated net profit for Q4FY26 was Rs 559.42 crore, up 35.16% QoQ from Rs 413.88 crore and 31.74% YoY from Rs 424.65 crore. For the full year FY26, consolidated net profit stood at Rs 1,938.10 crore, a decrease of 3.63% YoY from Rs 2,011.12 crore in FY25. Earnings Per Share (EPS): Consolidated basic EPS for Q4FY26 was Rs 13.44. Annual consolidated basic EPS for FY26 was Rs 46.35 compared to Rs 49.28 in FY25. Standalone Financial Highlights Revenue from Operations: For Q4FY26, revenue stood at Rs 2,581.82 crore, representing a decrease of 1.93% QoQ compared to Rs 2,632.68 crore in Q3FY26, but an increase of 21.81% YoY compared to Rs 2,119.46 crore in Q4FY25. For the full year FY26, revenue reached Rs 10,421.18 crore, marking a growth of 9.61% YoY over Rs 9,507.41 crore in FY25. Total Income: Total income for Q4FY26 was Rs 2,708.52 crore, an increase of 0.72% QoQ from Rs 2,689.20 crore and 15.80% YoY from Rs 2,338.97 crore. Annual total income for FY26 stood at Rs 10,747.28 crore, up 7.46% YoY compared to Rs 10,000.83 crore in FY25. Profit Before Tax (from continuing operations): PBT for Q4FY26 was Rs 788.01 crore, up 55.95% QoQ from Rs 505.29 crore and up 179.98% YoY from Rs 281.45 crore. Annual PBT for FY26 reached Rs 2,315.00 crore, an increase of 7.85% YoY from Rs 2,146.50 crore in FY25. Net Profit for the Period/Year: Net profit for Q4FY26 was Rs 713.61 crore, representing a growth of 58.98% QoQ from Rs 448.88 crore and 203.46% YoY from Rs 235.16 crore. For the full year FY26, net profit was Rs 2,037.56 crore, a growth of 14.09% YoY from Rs 1,785.99 crore in FY25. Earnings Per Share (EPS): Basic EPS for Q4FY26 improved to Rs 17.29 from Rs 10.87 in Q3FY26 and Rs 5.70 in Q4FY25. Annual basic EPS for FY26 was Rs 49.37 compared to Rs 44.22 in FY25. Business Highlights: Segment Performance: The Company and Group are primarily engaged in the business of manufacturing and trading pharmaceuticals and healthcare products. Consequently, they operate under a single reportable segment: "Pharmaceuticals". Dividend: The Board of Directors has recommended a final dividend of Rs 2 per equity share of face value of Re 1 each for the financial year 2025-26, subject to shareholder approval. Acquisition of Bharat Serums and Vaccines Limited (BSV): The Group completed the acquisition of 100% stake in BSV on October 23, 2024, for a cash consideration of Rs 13,768 crore. Acquisition of Women's Health Portfolio: Effective November 1, 2025, the Company acquired the Branded Generic Business relating to the Women's Health Portfolio from BSV for a consideration of Rs 797 crore. Exceptional Items: The Group recognized exceptional items of Rs 129.75 crore for FY26, primarily comprising an incremental impact of Rs 97.29 crore related to the notification of four new Labour Codes. Standalone results for FY26 included exceptional items of Rs 106.24 crore, which included Rs 87.22 crore for Labour Code impacts and Rs 19.02 crore for stamp duty related to IP assignment agreements. Investment in Subsidiary: The Board approved an additional investment of up to Rs 500 crore in Mankind Medicare Private Limited, a wholly owned subsidiary, for capacity expansion. NCD Redemption: The Company redeemed Non-Convertible Debentures (NCDs) worth Rs 1,250 crore on April 16, 2026. Management Changes: The Board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director for five years effective September 23, 2026. Mr. Pramod Gokhale resigned as Global Chief Information Officer effective May 31, 2026. Rajeev Juneja – Vice Chairman & Managing Director said: Revenue increased ~12% YoY with adj. EBITDA margins of 27.1% Overall domestic business (ex CH) grew by ~13%, led by: double-digit growth in Mankind domestic business led by 14.7% in cardiac and 11.6% in anti-diabetes (120 bps YoY increase in chronic share to ~40%) sequential growth recovery in key acute therapies like Gastro, VMN, etc. strong double-digit growth in BSVs domestic business OTC business grew by 20% led by strong growth in e-commerce; International business witnessed muted growth due to geo-political headwinds We are on track in strengthening scale and advancing specialization through four key pillars - steady base business, fast growing specialty chronic, high-potential OTC business, and super specialty BSV portfolio to deliver long-term sustainable growth. Result PDF

• Trendlyne
• 6 days 1 hour ago

Mankind Pharma posted a 30.4% rise in Q4FY26 profit, driven by strong demand for chronic therapies and OTC healthcare products

• Business Standard
• 6 days 11 hours ago